Navigation Links
Groundbreaking MS research to be presented at American Academy of Neurology Annual Meeting
Date:4/13/2010

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology (AAN) Annual Meeting, including a potential new drug for the treatment of multiple sclerosis (MS) and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.

  • "Oral Teriflunomide or Placebo Added to Glatiramer Acetate for 6 Months in Patients with Relapsing Multiple Sclerosis: Safety and Efficacy Results"
    (To be presented Wednesday, April 14, 2010 at 2:00 PM EDT.)

Mount Sinai researchers took part in a Phase II study of teriflunomide, an investigational oral medication for relapsing-remitting multiple sclerosis (RRMS), the most common form of the disease. The study analyzed teriflunomide added to ongoing treatment with glatiramer acetate, a currently prescribed medication, and determined that teriflunomide was safe and effective as part of combination therapy.

Researchers evaluated 123 patients with RRMS over 24 weeks. Patients were given teriflunomide in doses of seven mg/day or 14 mg/day, while a control group received a placebo. Study participants were evaluated through physical examination, laboratory data, electrocardiogram, pancreatic ultrasound, and MRI.

Teriflunomide had a positive safety profile, with only seven treatment emergent adverse events (TEAE) leading to treatment discontinuation. MRI studies revealed that teriflunomide also proved to be effective at reducing the size and volume of lesions on the brain.

"While our study was designed to evaluate the safety of teriflunomide, we determined that in addition to being safe it was also effective in reducing the size and number of lesions in people with RRMS," said Aaron Miller, MD, Professor of Neurology, and Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai School of Medicine. "Further data are required to evaluate efficacy of this combination therapy, but the results are promising."

  • "Trend Towards Lowering of Multiple Sclerosis Severity Scores Among More Recent Enrollees into the New York State Multiple Sclerosis Consortium"
    (To be presented Thursday, April 15, 2010 at 7:30 AM EDT )

Fred Lublin, MD, Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, and Dr. Miller are investigators on a study reviewing the efficacy of the Multiple Sclerosis Severity Score (MSSS), the measuring tool physicians use to determine increase of disability and the time needed to reach it, or the duration of the disease. The study was conducted with the New York State Multiple Sclerosis Consortium and compared disease severity in MS in the era of disease-modifying therapies (DMTs) to disease severity before DMTs were available. The study consisted of 6,238 MS patients, 57 percent of whom were on DMTs.

Results showed a significant decrease in MSSS per year of enrollment, meaning that in newer enrollees, disability and disease progression was less. Patients with relapsing-remitting multiple sclerosis showed the most significant change, especially those with more severe forms of the disease. A similar trend was noted in patients with progressive MS as well.

"There is a definitive shift to lower MS severity," said Dr. Lublin. "A number of factors may influence the decrease, including the effect of disease-modifying therapies or selection bias. Still, this is an exciting development that we will evaluate further."

  • "Is the Multiple Sclerosis Severity Score at Initial Presentation to an MS Comprehensive Care Center a Helpful Predictor of Long Term Outcome?"
    (Presented Tuesday, April 13, 2010 at 7:30 AM EDT.)

A second study involving the Multiple Sclerosis Severity Score analyzed whether it was an effective tool for measuring long-term disease outcomes. People with MS are often concerned about the ultimate course of their illness, and physicians typically advise their patients that the disease is ever-changing and that there is no way to predict its course. Researchers evaluated initial MSSS and tracked subsequent outcomes in 122 patients followed by a single physician, Dr. Miller.

Dr. Miller and his team determined that after 12 years nearly 80 percent of the patients were within one point or better of their initial MSSS score, indicating that MSSS is a good measurement for long-term multiple sclerosis outcomes.

"Ours is the first study to review changes in MSSS from initial consultation to 12 or more years later," Dr. Miller continued. "While more research is needed, these data indicate that MSSS may be an effective way to better predict the course of the disease."

  • Live Webinar on Controversial MS Treatment (Wednesday, April 14, 2010 at 12:00 p.m. EDT)

Dr. Miller will also participate in a live 90-minute webinar on Wednesday, April 14, 2010, hosted by the National Multiple Sclerosis Society and the American Academy of Neurology (AAN). Dr. Miller and the other panelists will discuss chronic cerebrospinal venous insufficiency (CCSVI), a controversial theory in MS treatment, and what it could mean to the future of people living with multiple sclerosis. The forum is open to journalists and the general public.


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Groundbreaking research shows platelets can reproduce in circulation
2. Statement by Blue Shield of California CEO Bruce Bodaken Regarding the Groundbreaking for the Family Violence Prevention Funds International Center
3. Groundbreaking Principal and Contributor on Dr. Oz Show Releases His Latest Book on How We Can Influence the Lives of Children
4. Texas-based consortium announces groundbreaking vaccine research program
5. $250,000 grant awarded for groundbreaking ligament and tendon repair research
6. $250,000 Grant Awarded for Groundbreaking Ligament and Tendon Repair Research
7. Groundbreaking Study Using Ultrasound for the Treatment of Intracerebral and Intraventricular Hemorrhage Stroke Shows Promise
8. Groundbreaking research to find vaccine for hepatitis C
9. LASIK Surgeons, Plastic Surgeons, Cosmetic Dentists and other Cash Paid Medical Specialists Brought Together for Groundbreaking Webinar Series
10. New research identifies modifiable risk factors for heart disease
11. Nuvo Research announces early redemption of 5% convertible debentures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, ... recipes for Memorial Day entertaining that are sure to satisfy your guests’ flavor ... sliced meats and cheeses featured in these refreshingly balanced recipes are packed with ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Yisrayl Hawkins, Pastor ... publication this week that is focusing on the Peace Agreements being discussed by President ... East sprint in a race to try to speed up peace talks in the ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a poignant ... of published author Laura Weigel Douglas, an avid reader who lives in the Pacific ... sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the impact ... the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and ... Walter. Walter and Jane have three adult children and a granddaughter. Walter ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... DIEGO , May 4, 2017  The American ... and Scientific Meeting— OBP Medical , a leading global ... the launch of a new extra-small size and first-in-market ... ER-SPEC vaginal specula. Already available in small, medium, ... makes OBP Medical,s line of single-use lighted specula the ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology: